Autologous Anti-CLDN18.2 TAC T-cells TAC01-CLDN18.2

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that have been genetically engineered to express a T-cell Antigen Coupler (TAC), comprised of a domain that targets the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) and another domain that binds to the endogenous T-cell receptor (TCR), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CLDN18.2 TAC T-cells TAC01-CLDN18.2 target and bind to CLDN18.2-expressing tumor cells and activate TCR-mediated signaling pathways, leading to T-cell-mediated killing of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

**Synonyms:** - Autologous Anti-CLDN18.2 T-cell Antigen Coupler-expressing T Cells TAC01-CLDN18.2 - Autologous Anti-claudin 18.2 TAC T Cells TAC01-CLDN18.2 - TAC 01-CLDN18.2 - TAC-01-CLDN18.2 - TAC-engineered T Cells TAC01-CLDN18.2 - TAC01-CLDN18.2